Overview

Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
- The purpose of this study is to find out whether combining a short course of chemotherapy (Fludarabine, Mitoxantrone and Rituximab) followed by Zevalin will be effective in treating relapsed mantle cell lymphoma. - The secondary purposes of the study are to determine the safety and to evaluate whether there is additional benefit from Zevalin therapy following the chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Biogen
Massachusetts General Hospital
Treatments:
Antibodies, Monoclonal
Fludarabine
Fludarabine phosphate
Mitoxantrone
Rituximab
Vidarabine